DexCom, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2521311074
USD
68.92
-0.15 (-0.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
DexCom, Inc.
IDEXX Laboratories, Inc.
Medtronic Plc
Intuitive Surgical, Inc.
Edwards Lifesciences Corp.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Stryker Corp.
Danaher Corp.
Abbott Laboratories
Becton, Dickinson & Co.

Why is DexCom, Inc. ?

1
Low Debt Company with Strong Long Term Fundamental Strength
  • Healthy long term growth as Net Sales has grown by an annual rate of 19.33% and Operating profit at 24.94%
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Capital Employed (avg) of 28.12% signifying high profitability per unit of total capital (equity and debt)
2
With a growth in Net Profit of 89.28%, the company declared Very Positive results in Mar 26
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 1,782.5 MM
  • INTEREST COVERAGE RATIO(Q) Highest at 10,400
  • ROCE(HY) Highest at 35.62%
3
With ROCE of 45.37%, it has a attractive valuation with a 11.58 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -13.68%, its profits have risen by 45.1% ; the PEG ratio of the company is 0.6
4
Rising Promoter Confidence
  • Promoters have increased their stake in the company by 0.58% over the previous quarter and currently hold 1.06% of the company
  • Promoters increasing their stake is a sign of high confidence in the future of the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to DexCom, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is DexCom, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
DexCom, Inc.
-13.68%
-1.01
40.41%
S&P 500
22.24%
1.67
13.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
19.33%
EBIT Growth (5y)
24.94%
EBIT to Interest (avg)
18.63
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.87
Tax Ratio
26.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
28.12%
ROE (avg)
20.44%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
8.74
EV to EBIT
25.53
EV to EBITDA
20.00
EV to Capital Employed
11.58
EV to Sales
4.99
PEG Ratio
0.63
Dividend Yield
NA
ROCE (Latest)
45.37%
ROE (Latest)
30.46%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 1,782.5 MM

INTEREST COVERAGE RATIO(Q)

Highest at 10,400

ROCE(HY)

Highest at 35.62%

RAW MATERIAL COST(Y)

Fallen by -16.72% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -34.85 %

PRE-TAX PROFIT(Q)

At USD 269.5 MM has Grown at 74.66%

NET PROFIT(Q)

At USD 199.5 MM has Grown at 89.28%

-1What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 4,413.9 MM

Here's what is working for DexCom, Inc.

Interest Coverage Ratio
Highest at 10,400 and Grown
In each period in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow
Highest at USD 1,782.5 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
At USD 269.5 MM has Grown at 74.66%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 199.5 MM has Grown at 89.28%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -34.85 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -16.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 67.1 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for DexCom, Inc.

Cash and Eqv
Lowest at USD 4,413.9 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents